Seattle-Based Pharma Co. Awarded $74MM DOD Contract for Drug Production

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $74 million for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting orthopoxviruses. Under the contract, Just – […]